$GTCH Special Edition AI Eye Podcast - GBT Technologies CTO Shares Update on Hippocrates Health Advisor Agent
https://www.newsfilecorp.com/release/105283
Point Roberts, Washington and Vancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - Investorideas.com (https://www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today's special edition of The AI Eye Podcast featuring an exclusive interview with Danny Rittman, CTO of the technology company, GBT Technologies Inc. (OTC Pink: GTCH).
Listen to today's podcast:
https://www.investorideas.com/Audio/Podcasts/...AI-Eye.mp3
Hear the Ai Eye on Spotify
Hippocrates, the recently announced health advisory system from GBT Technologies Inc. (OTC Pink: GTCH), will leverage AI technology to cull and analyze masses of medical and health information, according to the company's CTO, Danny Rittman.
"We incorporate big data, and do analysis with a wide variety of algorithms which we developed based on deep learning and machine learning," he said. "And we're going to use it for a supervised AI system that can basically take vast amounts of information and conclude on advice to the user."
Rittman explained that the system was conceived of during the COVID-19 pandemic, as an offshoot of GBT's existing Avant! AI.
"The Hippocrates system started at the time because of COVID-19, as a health advisor and an expert in the respiratory system and respiratory disease and illness due to COVID," he said. "The idea was born a little bit more than a year ago. It's actually a derivative of our Avant! AI, and at the time we knew the company was going into the medical arena."
According to the press release for Hippocrates, GBT taught Avant! medical information through the use of "accredited medical textbooks used in medical schools," allowing it to "learn the information to provide first line, health related advice and tips."
"The idea is to turn Hippocrates into a broader health-related advisor, but as a first line only," Rittman said. According to the press release, the company also:
"…plans to connect with governmental and professional accredited data resources, among them are the CDC (Center of Disease Control and Prevention - Centers for Disease Control and Prevention (cdc.gov)) and the NCBI (National Center for Biotechnology Information - National Center for Biotechnology Information (nih.gov)), as additional references."
Hippocrates will work by understanding a user's question, analyzing the information drawn from its aforementioned vast resources, and formulate a conclusion and advise the user accordingly. The system's big data incorporates components of data mining, statistics, and predictive analysis, extracting knowledge and insights from huge amounts of information.
GBT plans to pair Hippocrates with its qTerm human vital signs device next year, as well. Rittman said this will occur once web and mobile applications have been completed for Hippocrates.
"We believe that integrating qTerm with Hippocrates is a natural stage that we'll go through," he said. "We expect that to probably happen six months from now since we're still training Hippocrates and want to build it a mobile application, a new interface."
The qTerm, like Hippocrates, employs AI, but also measures a user's body temperature, blood oxygen level, and heart rate. Currently, the qTerm's AI provides ongoing health monitoring based on the data it measures, but Rittman explained the significance of integrating Hippocrates.
"It's not going to be just another thing like temperature or an oximeter that takes your vitals," he said. "It's actually going to be a whole system behind the scenes running, the same as the qTerm, with a user account, all private and secure, and will become a health assistant."
https://www.newsfilecorp.com/release/105283
Point Roberts, Washington and Vancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - Investorideas.com (https://www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today's special edition of The AI Eye Podcast featuring an exclusive interview with Danny Rittman, CTO of the technology company, GBT Technologies Inc. (OTC Pink: GTCH).
Listen to today's podcast:
https://www.investorideas.com/Audio/Podcasts/...AI-Eye.mp3
Hear the Ai Eye on Spotify
Hippocrates, the recently announced health advisory system from GBT Technologies Inc. (OTC Pink: GTCH), will leverage AI technology to cull and analyze masses of medical and health information, according to the company's CTO, Danny Rittman.
"We incorporate big data, and do analysis with a wide variety of algorithms which we developed based on deep learning and machine learning," he said. "And we're going to use it for a supervised AI system that can basically take vast amounts of information and conclude on advice to the user."
Rittman explained that the system was conceived of during the COVID-19 pandemic, as an offshoot of GBT's existing Avant! AI.
"The Hippocrates system started at the time because of COVID-19, as a health advisor and an expert in the respiratory system and respiratory disease and illness due to COVID," he said. "The idea was born a little bit more than a year ago. It's actually a derivative of our Avant! AI, and at the time we knew the company was going into the medical arena."
According to the press release for Hippocrates, GBT taught Avant! medical information through the use of "accredited medical textbooks used in medical schools," allowing it to "learn the information to provide first line, health related advice and tips."
"The idea is to turn Hippocrates into a broader health-related advisor, but as a first line only," Rittman said. According to the press release, the company also:
"…plans to connect with governmental and professional accredited data resources, among them are the CDC (Center of Disease Control and Prevention - Centers for Disease Control and Prevention (cdc.gov)) and the NCBI (National Center for Biotechnology Information - National Center for Biotechnology Information (nih.gov)), as additional references."
Hippocrates will work by understanding a user's question, analyzing the information drawn from its aforementioned vast resources, and formulate a conclusion and advise the user accordingly. The system's big data incorporates components of data mining, statistics, and predictive analysis, extracting knowledge and insights from huge amounts of information.
GBT plans to pair Hippocrates with its qTerm human vital signs device next year, as well. Rittman said this will occur once web and mobile applications have been completed for Hippocrates.
"We believe that integrating qTerm with Hippocrates is a natural stage that we'll go through," he said. "We expect that to probably happen six months from now since we're still training Hippocrates and want to build it a mobile application, a new interface."
The qTerm, like Hippocrates, employs AI, but also measures a user's body temperature, blood oxygen level, and heart rate. Currently, the qTerm's AI provides ongoing health monitoring based on the data it measures, but Rittman explained the significance of integrating Hippocrates.
"It's not going to be just another thing like temperature or an oximeter that takes your vitals," he said. "It's actually going to be a whole system behind the scenes running, the same as the qTerm, with a user account, all private and secure, and will become a health assistant."
